Welcome to our dedicated page for Banco Santander SEC filings (Ticker: SAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Banco Santander, S.A. (SAN) SEC filings page on Stock Titan provides access to the bank’s U.S. regulatory disclosures, primarily filed on Form 6-K as a foreign private issuer and related forms. These documents offer detail on capital actions, securities issuance and other matters relevant to holders of Santander securities.
Recent Form 6-K filings describe the bank’s share buyback programme of its own ordinary shares, including weekly updates on purchases across European trading venues, cumulative cash invested and the proportion of outstanding shares repurchased since 2021. A December 30, 2025 filing reports a capital reduction through cancellation of own shares and quantifies the total number of shares repurchased and the resulting reduction in share capital.
Other 6-Ks cover the optional early redemption of 4.375% Non-Step-Up Non-Cumulative Contingent Convertible Perpetual Preferred Tier 1 Securities (CoCos), and the issuance of Senior Non Preferred Notes due 2030 and 2035, with associated underwriting agreements and indenture supplements incorporated into a registration statement on Form F-3. These filings help investors understand Santander’s funding structure and capital instruments.
The filings section also includes a Form 25-NSE filed by the New York Stock Exchange regarding the removal from listing and/or registration of the Guarantor of Series 26 Subordinated Debt Securities due November 2025. This form relates to that specific class of subordinated debt securities.
On Stock Titan, these documents are updated as they are released to EDGAR. AI-powered tools can assist users by summarizing lengthy 6-K attachments, highlighting key figures in capital actions, and clarifying the implications of forms such as 6-K, F-3 exhibits and Form 25 for Banco Santander, S.A. security holders.
Banco Santander has provided an update on its share buyback programme, detailing purchases of its own shares between 21 and 27 August 2025. During this period, the bank repurchased a total of 5,176,565 shares across several trading venues at weighted average prices around €8 per share.
The cash amount invested in the buyback programme up to 27 August 2025 is €297,730,065, which the bank states represents approximately 17.5% of the programme’s maximum investment amount. Overall, Banco Santander indicates it has repurchased approximately 14.4% of its outstanding shares as of 2021 through this programme.
Banco Santander reports progress on its ongoing share buyback programme. Between 14 and 20 August 2025, the bank repurchased 5,000,000 ordinary shares across several trading venues at weighted average prices ranging from €8.1189 to €8.2546 per share.
As of 20 August 2025, the total cash amount invested in the programme reaches €255,528,215, which is about 15% of the maximum investment amount approved for the buyback. The bank states that, with these purchases, it has repurchased approximately 14.4% of its outstanding shares as of 2021.
Banco Santander, S.A. submitted a Form 25 notification indicating the removal of a class of its securities from listing and/or registration on the New York Stock Exchange LLC. The filing names the issuer and exchange and references the applicable SEC rules for delisting and withdrawal procedures. The document does not specify the exact class of securities being removed, the effective date of removal, which rule box was checked, or a signed certifying official.
Banco Santander reported execution of its announced buyback programme between 7 and 13 August 2025. To 13 August the Bank has spent €214,649,085, representing approximately 12.6% of the programme's maximum investment. During that week the Bank repurchased a total of 7,350,000 ordinary shares across trading venues XMAD, CEUX, TQEX and AQEU, at weighted average prices ranging from about €7.71 to €8.10. The filings state these purchases amount to roughly 14.3% of outstanding shares as of 2021 and refer to the earlier Buyback Commencement Communication of 30 July 2025.
Banco Santander, S.A. (SAN) released the results of the 2025 EBA/ECB stress-test covering 2024-27.
- Starting capital: Fully-loaded CET1 12.19% and Phased-in CET1 12.78% at 31-Dec-24 (adjusted for CRR3 and EBA methodology).
- Baseline scenario: Fully-loaded CET1 strengthens to 13.58% (2025), 14.56% (2026) and 14.65% (2027); phased-in rises to 15.31% by 2027.
- Adverse scenario: Fully-loaded CET1 declines to 10.46% in 2025, recovers to 11.12% in 2026, and returns to 10.46% in 2027 (≈-1.7 pp vs. start). Phased-in bottoms at 10.91%.
The bank therefore projects capital accretion in the central case and a limited draw-down under stress while maintaining double-digit CET1 throughout the horizon. Figures reflect the phased implementation of CRR3 and IFRS 9.
Banco Santander (SAN) has authorised a €1.7 billion share buyback, equivalent to c.25% of the Group’s H1-25 underlying profit and one-half of its 50% total-payout target. The programme, already cleared by regulators, will start on 31 July 2025 and may run until 3 January 2026 unless the full amount is reached earlier.
Key terms:
- Purpose: shares acquired will be cancelled, lowering share capital as approved at the 2025 AGM.
- Maximum cash outlay: €1.7 bn.
- Share cap: ≤1,373,961,787 shares; at the €7.55 closing price on 28 Jul 25 this implies 225.2 m shares (c.1.51% of current capital).
- Pricing limits: purchase price may not exceed the higher of the last independent trade or highest independent bid.
- Volume limits: ≤25% of the 20-day average daily volume per trading day.
- Venues: Spanish Mercado Continuo, Turquoise Europe, DXE Europe, Aquis Exchange Europe.
- Disclosure: transactions published within seven market sessions.
The board intends to decide on an interim cash dividend against 2025 earnings on 30 September 2025; remaining 2025 shareholder remuneration will depend on future corporate and regulatory approvals.